Sign In
Buy ARCT
$5.76
-0.160 (-2.70%)
At Close: Jul 31, 2026
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
01:04pm, Wednesday, 21'st Feb 2024
Biotech stocks are often at the forefront of innovation. These are the companies we hear about that are driving breakthroughs in healthcare.
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
04:39pm, Tuesday, 20'th Feb 2024
We've all heard the story with AI by now, and for good reason. It has massive potential to overhaul almost every aspect of our lives.
Study conducted by Meiji Seika Pharma in Japan Short communication follows previously published data in The Lancet Infectious Diseases demonstrating Immunological Non-Inferiority to Wuhan Strain a
Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID Treatments
11:25am, Friday, 02'nd Feb 2024
Arcturus Therapeutics is a biotechnology company specializing in rare and infectious diseases, with approved COVID and influenza vaccines in Japan and the EU. The company is developing game-changing t
Arcturus: H1 2024 Rare Disease Drug Data On Deck
05:20pm, Wednesday, 31'st Jan 2024
Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic
KING OF PRUSSIA, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publicat
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
12:03pm, Sunday, 17'th Dec 2023
With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
10:39pm, Wednesday, 13'th Dec 2023
With such a high demand for items that can improve our longevity and health, biotechnology is at the forefront of today's innovation. Biotech products allow us to better understand the human body and
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 04'th Dec 2023
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company
Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up
09:01am, Tuesday, 28'th Nov 2023
Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.
From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving Journey
03:01am, Friday, 17'th Nov 2023
Arcturus Therapeutics is a biotech firm focused on mRNA vaccine development and delivery technologies. The company's core investment thesis is centered around its cutting-edge research and its ability
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript
08:38pm, Tuesday, 14'th Nov 2023
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
10:56am, Tuesday, 14'th Nov 2023
These companies in the biotechnology sector are doing incredible work and achieving wonderful developments. The result is not not only growth and profit for the companies, but they are also offering e
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023
04:01pm, Wednesday, 25'th Oct 2023
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company
Arcturus: Interim Readout Of Rare Disease Data In Coming Months
05:35am, Thursday, 07'th Sep 2023
Results from phase 2 study using ARCT-810 for the treatment of patients with Ornithine-Transcarbamylase [OTC] deficiency are expected in the coming months. The Ornithine-Transcarbamylase Deficiency ma
